Vontobel Holding’s Aclaris Therapeutics ACRS Stock Holding History

Vontobel Holding’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$95.2K	Sell	18,000 -7,000	-28%	-$31.2K	﹤0.01%	1413
2026 Q1	$93.8K	Sell	25,000 -1,000	-4%	-$3.37K	﹤0.01%	1152
2025 Q4	$78.3K	Hold	26,000	–	–	﹤0.01%	1381
2025 Q3	$49.4K	Hold	26,000	–	–	﹤0.01%	1325
2025 Q2	$36.9K	Buy	26,000 +4,000	+18%	+$5.41K	﹤0.01%	1246
2025 Q1	$33.7K	Buy	22,000 +6,000	+38%	+$12.8K	﹤0.01%	1077
2024 Q4	$39.7K	Sell	16,000 -4,000	-20%	-$9.95K	﹤0.01%	1083
2024 Q3	$23K	Hold	20,000	–	–	﹤0.01%	1071
2024 Q2	$22K	Hold	20,000	–	–	﹤0.01%	1060
2024 Q1	$24.8K	Sell	20,000 -10,268	-34%	-$12.2K	﹤0.01%	1070
2023 Q4	$31.8K	Buy	30,268 +17,040	+129%	+$52K	﹤0.01%	1083
2023 Q3	$90.6K	Sell	13,228 -1,000	-7%	-$8.54K	﹤0.01%	1024
2023 Q2	$148K	Hold	14,228	–	–	﹤0.01%	1029
2023 Q1	$115K	Buy	+14,228	New	+$181K	﹤0.01%	1022

Other funds holding ACRS

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Vontobel Holding's ACRS Position: Q2 2026 in Review

Vontobel Holding reduced its Aclaris Therapeutics (ACRS) stake by 28% in Q2 2026, selling an estimated $31.2K and leaving 18,000 shares worth $95.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1413.

Vontobel Holding first reported a position in ACRS in Q1 2023 and has held it in 14 quarters since. The position peaked at $148K in Q2 2023. 148 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

Vontobel Holding held 18,000 shares of Aclaris Therapeutics worth $95.2K as of Q2 2026.
Vontobel Holding sold 7,000 Aclaris Therapeutics shares in Q2 2026, an estimated $31.2K.
Aclaris Therapeutics made up ﹤0.01% of Vontobel Holding's portfolio in Q2 2026, its #1413 holding.
Vontobel Holding first reported a position in Aclaris Therapeutics in Q1 2023 and has held it in 14 quarters since.
Vontobel Holding's Aclaris Therapeutics position peaked at $148K in Q2 2023.
148 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Vontobel Holding's 13F filing for Q2 2026, filed 3 Aug 2026.